Abstract
Variants of the human K562 were developed against the nucleoside analogues cytosine arabinoside, 2 chlorodeoxyadenosine, fludarabine and gemcitabine. The resistant lines displayed a high degree of cross-resistance to all nucleoside analogues, with little or no cross resistance to other agents. There was a profound accumulation defect of the different nucleoside analogues in all of the variants. There was a strong overexpression of 5’ nucleotidase, measured by rt-PCR and enzyme activity, in all resistant variants. There was a two fold increase of ribonucleotide reductase in the fludarabine resistant line and increased expression of purine nucleoside phosphorylase in the 2 chlorodeoxyadenosine selected line. Karyotypic analysis revealed the loss of a 6(q16;q22) deletion present in the parental line in all of the resistant lines. This portion of chromosome 6 has been shown to contain the gene for 5′nucleotidase. Early events in the transport and metabolism appear to be involved in the resistance mechanisms to nucleoside analogues and are responsible for broad cross resistance to this family of compounds.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cheson, B. D. New antimetabolites in the treatment of human malignancies, Semin Oncol. 19: 695–706, 1992.
Ellison, R. R., Holland, J. F., and M., W. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults, Blood. 32: 507–523, 1968.
Juliusson, G., Christiansen, I., Hansen, M. M., Johnson, S., Kimby, E., Elmhorn-Rosenborg, A., and Liliemark, J. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia, J Clin Oncol. 14: 2160–2166, 1996.
Keating, M. J., O’Brien, S., Kantarjian, H., Plunkett, W., Estey, E., Koller, C., Beran, M., and Freireich, E. J. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent, Blood. 11: 2878–2884, 1993.
Tesch, H., Santoro, A., Fiedler, F., Bonadonna, G., Bredenfeld, H., Oliva, C., Buksmaui, S., Sieber, M., and Diehl, V. Phase II study of gemcitabine in pretreated Hodgkin’s disease results of a multicenter study. In: American Society of Hematology, San Diego, 1997.
Richel, D. J., Colly, L. P., Arkesteijn, G. J. A., Arentsen-Honders, M. W., Kerster, M. G. D., ter Riet, P. M., and Willemze, R. Substrate-specific deoxycytidine kinase deficiency in 1-b-D-arabinofuranosylcytosine-resistant leukemic cells, Cancer Res. 50: 6515–6519, 1990.
Whelan, J., Smith, T., Phear, G., Rohatiner, A., Lister, A., and Meuth, M. Resistance to cytosine arabinoside in acute leukemia: the significance of mutations in CTP synthetase, Leukemia. 8: 264–265, 1994.
Griffiths, M., Beaumont, N., Yao, S. Y. M., Sundaram, M., Boumah, C. E., Davies, A., Kwong, F. Y. P., Coe, I., Cass, C. E., Young, J. D., and Baldwin, S. A. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs, Nature Med. 3: 89–93, 1997.
Ujhazy, P., Berleth, E. S., Pietkiewicz, J. M., Kitano, H., Skaar, J. R., Ehrke, M. J., and Mihich, E. Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance, Int J Cancer. 68: 493–500, 1996.
Choy, B. K., McClarty, G. A., Chan, A. K., Thelander, L., and Wright, J. A. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations, Cancer Res. 48: 2029–2035, 1988.
Warzocha, K., Fabianowska-Majewska, K., Blonski, J., Krykowski, E., and Robak, T. 2 chloro deoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukemia, Eur J Cancer. 33: 170–173, 1996.
Gandhi, V., Huang, P., Chapman, A. J., Chen, F., and Plunkett, W. Incorporation of fludarabine and 1-β-D-arabinofuranosylcytosine 5′-triphosphates by DNA polymerase α: affinity, interaction and consequences, Clin Cancer Res. 3: 1347–1355, 1997.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Dumontet, C. et al. (1999). Common Resistance Mechanisms to Nucleoside Analogues in Variants of the Human Erythroleukemic Line K562. In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_63
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4811-9_63
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7180-9
Online ISBN: 978-1-4615-4811-9
eBook Packages: Springer Book Archive